virginiamycin and Opportunistic-Infections

virginiamycin has been researched along with Opportunistic-Infections* in 2 studies

Other Studies

2 other study(ies) available for virginiamycin and Opportunistic-Infections

Article	Year
Treatment of central nervous system infection by vancomycin-resistant enterococcus faecium. Diagnostic microbiology and infectious disease, 2003, Volume: 45, Issue:3 Enterococci are uncommon causes of CNS infection. We describe a case of ventriculitis and Ommaya reservoir infection due to vancomycin-resistant Enterococcus faecium successfully treated with the combination of i.v. quinupristin/dalfopristin and i.v. linezolid. The patient deteriorated after receiving three dosages of intraventricular quinupristin/dalfopristin. He recovered after discontinuation of intraventricular quinupristin/dalfopristin. Topics: Aged; Brain Neoplasms; Central Nervous System Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterococcus faecium; Follow-Up Studies; Gram-Positive Bacterial Infections; Humans; Injections, Intralesional; Lymphoma; Male; Opportunistic Infections; Risk Assessment; Treatment Outcome; Vancomycin; Virginiamycin	2003
RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium. The Journal of infection, 1998, Volume: 36, Issue:3 We describe three cases of Enterococcus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients. Topics: Adolescent; Adult; Anti-Bacterial Agents; Enterococcus faecium; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Opportunistic Infections; Virginiamycin	1998

Article

Year

Treatment of central nervous system infection by vancomycin-resistant enterococcus faecium.

Diagnostic microbiology and infectious disease, 2003, Volume: 45, Issue:3

Enterococci are uncommon causes of CNS infection. We describe a case of ventriculitis and Ommaya reservoir infection due to vancomycin-resistant Enterococcus faecium successfully treated with the combination of i.v. quinupristin/dalfopristin and i.v. linezolid. The patient deteriorated after receiving three dosages of intraventricular quinupristin/dalfopristin. He recovered after discontinuation of intraventricular quinupristin/dalfopristin.

Topics: Aged; Brain Neoplasms; Central Nervous System Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterococcus faecium; Follow-Up Studies; Gram-Positive Bacterial Infections; Humans; Injections, Intralesional; Lymphoma; Male; Opportunistic Infections; Risk Assessment; Treatment Outcome; Vancomycin; Virginiamycin

2003

RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium.

The Journal of infection, 1998, Volume: 36, Issue:3

We describe three cases of Enterococcus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients.

Topics: Adolescent; Adult; Anti-Bacterial Agents; Enterococcus faecium; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Opportunistic Infections; Virginiamycin

1998